重庆华森制药股份有限公司 2025 年半年度报告全文 重庆华森制药股份有限公司 2025 年半年度报告 二零二五年八月 1 重庆华森制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、董事及高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人游洪涛、主管会计工作负责人游洪涛及会计机构负责人(会计 主管人员)彭晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司 2025 年半年度报告涉及的未来计划等前瞻性陈述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。风险因素详见本报告第三节"管 理层讨论与分析"中"十、公司面临的风险和应对措施"相关内容。 公司经本次董事会审议通过的利润分配预案为：拟以 2025 年 6 月 30 日 登记的总股本 417,596,314 股为基数，向全体股东每 10 股派发现金红利 0.35 元（含税），送红股 0 股（含税），不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 2 ...

重庆华森制药股份有限公司 关于公司2025年半年度利润分配预案的公告 证券代码：002907 证券简称：华森制药 公告编号：2025-068 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、2025年半年度利润分配预案的审议程序 重庆华森制药股份有限公司（以下简称"公司"）于2025年8月21日召开第 四届董事会第二次会议、第四届董事会审计委员会第二次会议，审议通过《关 于公司〈2025年半年度利润分配预案〉的议案》。鉴于公司2024年年度股东会 已审议通过《关于授权董事会制定2025年中期分红方案的议案》，同意授权董 事会在授权范围内制定并实施2025年中期分红方案，且本次利润分配预案在股 东会对董事会的授权范围内，本次利润分配事项无需再提交股东会审议。现将 相关情况公告如下： 二、公司2025年半年度利润分配预案的基本情况 根据公司2025年半年度财务报告（未经审计），公司2025年半年度合并报 表实现归属于上市公司股东的净利润为53,950,516.43元，提取法定盈余公积金 0元，加上年初未分配利润681,631,632.32元，减去2024年度对 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-064 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝 20150018），本次变更主要 涉及增加生产范围（仅限注册申报使用）、核减受托生产（仅限注册申报使用）和 新增受托生产。具体情况如下： 一、变更内容 1.重庆市荣昌区昌州街道板桥路 143 号增加生产范围（仅限注册申报使用）： 片剂（含抗肿瘤类）； 2.核减受托生产（仅限注册申报使用）：委托方是重庆星创医药有限公司，受 托品种是奥利司他胶囊（国药准字 H20103180），生产场地是重庆市荣昌区昌州街 道板桥路 143 号 503 车间硬胶囊剂生产线，受托有效期至 2025 年 11 月 9 日； 3.新增受托生产：委托方是重庆星创医药有限公司，受托品种是奥利司他胶囊 （国药准字 H20103180），生产场地是重庆市荣昌区昌州街道板桥路 143 号 503 车 间 ...

Core Viewpoint - Huason Pharmaceutical has received drug re-registration approval for two products, indicating a positive development in its product portfolio and market presence [1][2]. Group 1: Product Details - The company received approval for "Pediatric Throat and Tonsil Granules," which is used for treating symptoms like sore throat and cough in children [1]. - The second product, "Injectable Glycyrrhizin Ammonium," is indicated for acute and chronic viral hepatitis with elevated ALT levels, showcasing its comprehensive liver protection effects [2]. Group 2: Market Insights - The pediatric traditional Chinese medicine market in China is projected to reach 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [1]. - The approval of these products aligns with the growing demand for pediatric medications, particularly in the context of rising sales in the sector [1]. Group 3: Regulatory and Quality Assurance - The approval ensures the normal production and sales of the mentioned drugs, with the company committing to strict quality control measures [2]. - The injectable glycyrrhizin ammonium has been included in several national and international liver disease management guidelines, reinforcing its credibility and market position [2].

一、《药品再注册批准通知书》主要信息 （一）小儿咽扁颗粒 药 品 通 用 名 称：注射用甘草酸二铵 英 文 名 / 拉 丁 名：Diammonium Glycyrrhizinate for Injection 受 理 号：CYHZ2540457 渝 证券代码：002907 证券简称：华森制药 公告编号：2025-063 重庆华森制药股份有限公司 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 2 个药品的《药品再注 册批准通知书》。现将相关情况公告如下： | 药 | 品 | 通 | | 用 | 名 | 称：小儿咽扁颗粒 | | --- | --- | --- | --- | --- | --- | --- | | 受 | | | 理 | | | 号：CYZZ2417666 渝 | | 通 | 知 | | 书 | | 编 | 号：2025R075783 | | 剂 | | | | | | 型：颗粒剂 | ...

Group 1: Company Performance and Market Development - The company has achieved significant breakthroughs in overseas markets, with its fifth production base passing the FDA's cGMP inspection in May 2023, establishing a high standard for its GMP management system [2][3] - Key traditional Chinese medicine products have received registration approvals in Singapore, marking a milestone for the company's international product pipeline [3] - Revenue from the five key traditional Chinese medicine products increased by 24.49% year-on-year in Q1 2025, with 甘桔冰梅片 showing a remarkable growth of 54.36% [6][7] Group 2: Research and Development Progress - The company has integrated its R&D capabilities through a majority stake in Chengdu Aorui Pharmaceutical, enhancing its small molecule innovative drug development capacity [4] - Currently, there are 7 innovative drug projects in the pipeline, targeting various cancers and autoimmune diseases, with the lead project ORIC-1940 in clinical trials [4][5] - The company has filed 35 patents, including 17 PCT patents, demonstrating its commitment to innovation [5] Group 3: Product Strategy and Market Positioning - The company is actively working on extending the protection period for its key traditional Chinese medicine products, with two products receiving a 7-year extension [6] - The company has received 32 recommendations from authoritative sources, reflecting the clinical and market value of its products [7] - The sales distribution remains heavily focused on public hospitals, with approximately 70% of sales occurring in-hospital, while efforts are being made to expand into retail and e-commerce channels [8][9] Group 4: Special Medical Foods and Future Plans - The company has four self-researched special medical food projects, with one project recently receiving regulatory approval, marking a significant entry into this market [10] - The company is exploring digital marketing strategies through various online platforms to enhance product visibility and sales [10] Group 5: Clinical Trials and Future Expectations - The company anticipates data from the ORIC-1940 clinical trial in 2024, with expectations for it to address safety concerns associated with existing therapies [11] - The board is considering implementing an equity incentive plan based on the company's development and market conditions [12]

Group 1 - The stock of Aonlikang is approaching a limit down, indicating significant selling pressure [1] - Several pharmaceutical companies, including Nanjing New Pharmaceutical, Huason Pharmaceutical, Yuekang Pharmaceutical, Chenxin Pharmaceutical, Guizhou Bailing, and Shutaishen, have all experienced declines exceeding 6% [1]

二、对公司的影响 重庆华森制药股份有限公司 关于公司缴纳税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）近期对纳税义务履行情 况开展了自查，现将有关情况公告如下： 一、基本情况 公司在日常税务合规自查过程中，对公司可转换公司债券相关财税处理进 行了专项复核，经全面自查确认，因可转债利息费用的税会处理差异，需补缴 企业所得税 7,174,740.43 元，企业所得税滞纳金 2,844,784.58 元。 截至本公告披露日，公司已将上述税款及滞纳金缴纳完毕，主管税务部门 未对该事项给予处罚。 证券代码：002907 证券简称：华森制药 公告编号：2025-062 根据《企业会计准则第 28 号—会计政策、会计估计变更和差错更正》相关 规定，上述事项不属于前期会计差错，不涉及前期财务数据追溯调整。公司补 缴上述税款及滞纳金将计入 2025 年当期损益，预计将影响公司 2025 年度归属 于上市公司股东的净利润 10,019,525.01 元，最终财务数据以 2025 年度经审计 的财务报表为准。本事项不会对公司 ...

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities due to favorable policies and market developments, with a notable surge in stock performance among TCM companies [6][9]. Market Performance - On August 1, the A-share market saw a slight decline, with the Shanghai Composite Index down 0.37%, Shenzhen Component Index down 0.17%, and ChiNext Index down 0.24%. However, over 3,300 stocks rose in the market [1][2]. - The TCM sector led the market with a substantial increase, as evidenced by the 1.78% rise in the Shenwan TCM Index, with several companies, including Weikang Pharmaceutical and Tianmu Pharmaceutical, hitting the daily limit [5][6]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research and development [6]. - The State Council's 2025 directive emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [6]. Company Performance - Notable TCM companies reported significant profit growth in the first half of 2025. For instance, Darentang's net profit is expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [9][11]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [9][11]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced sales in pharmaceuticals and medical devices [10]. Investment Insights - Analysts suggest that the TCM sector is poised for growth, driven by innovative products and strong brand recognition, particularly in high-value markets [7][8]. - The focus on stable cash flow to support R&D expenditures is expected to be a key strategy for TCM companies moving forward [7].